drugset / Trial / NCT01259544
BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency
Phase 2
Completed
33 enrolled
Meridian Bioscience, Inc.
Asian Institute of Gastroenterology, Hyderabad, India · collabVirginia Commonwealth University · collab
Non-randomizedCrossoverSingle-blindDiagnostic
Summary
13C breath di-peptide tests are an effective non-invasive tool to detect pancreatic exocrine function in patients with Chronic Pancreatitis.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | benzoyl-L-tyrosyl-[1-13C]alanine | Peptide | 300 mg | — |